GlobalData is the parent company of Clinical Trials Arena. "Ocugen sets sights on Phase III after GA gene therapy win" was ...

"Regulatory flexibility must be tailored for cell and gene therapies," commented FDA Commissioner Marty Makary. "These are ...

Cell and gene therapies present promising opportunities, especially in oncology, blood disorders, and neurology. Investors prioritize scalable platforms and clear regulatory paths. Focus has shifted ...

The cell and gene therapy sector has never lacked attention, but all too often, the narrative swings from one extreme to ...

Ocugen, Inc. gene therapy outlook: key 2026 catalysts, Phase 2/3 eye-disease data, BLA plans to 2028, and risks. Click for ...

Sarepta Therapeutics saw its stock skid 11% after the company announced preliminary unaudited 2025 sales results that missed analyst forecasts for its marketed Elevidys® (delandistrogene ...

The AI model "Eden" is intended to generate new gene therapies for cancer and rare diseases, as well as active ingredients ...

Huntington's disease (HD) has long been impossible to cure, but new research is finally giving fresh hope. HD is a ...

Sadly, there is no cure for Huntington’s disease. But a couple new research papers suggests this may be about to change.

The landscape of next-generation sequencing (NGS) continues to be defined by astonishing technological progress. We continue ...

Sickle cell anemia is the world's most common genetic disorder. It causes the red blood pigment hemoglobin to crystallize, ...